Report
Oussema Denguir

GlaxoSmithKline : Bad news for Nucala in the US in COPD

>US experts recommend against Nucala in COPD - Yesterday morning, the FDA expert panel (Pulmonary Allergy Drugs Advisory Committee) voted against approving Nucala (mepolizumab) in COPD (chronic obstructive pulmonary disease): 3 votes for / 16 against on the drug’s risk-benefit profile. The experts are not convinced of the treatment’s efficacy (3 for / 16 against) but believe there is adequate evidence of its safety (17 for / 2 against). The PDUFA date (FDA approval de...
Underlying
GlaxoSmithKline PLC CEDEAR

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Oussema Denguir

Other Reports on these Companies
Other Reports from Oddo BHF
Matthias Desmarais
  • Matthias Desmarais

ResearchPool Subscriptions

Get the most out of your insights

Get in touch